Firdapse amifampridine 3: Phase III ongoing

Catalyst said an IDMC recommended continuation of a double-blind, placebo-controlled, international Phase III trial of Firdapse based on a review of safety and clinical data. The trial is evaluating Firdapse given 3-4 times daily in about 30 patients, who will receive a total daily dose of 30-80 mg, except in patients with moderate renal impairment, who will receive a starting dose of 10 mg. ...